Unscrupulous athletes may soon find it much harder to get away with juicing. Anti-doping agencies are trying out “biological passports,” electronic records for individual athletes which provide baseline measurements of substances in their blood and urine. The record is built up over time through repeated sampling, and later tests can look for suspicious changes that may indicate the use of performance enhancing substances. As cycling has been particularly hammered by allegations of doping athletes, the International Cycling Agency has lead the charge on biological passports. Over a year, it took around 8300 blood samples from 804 cyclists. It recently revealed that a small number of these athletes’ profiles are “under further scrutiny” [New Scientist].
Doping has gone far beyond obvious substances like steroids; in recent years athletes have been caught injecting hormones for a competitive edge, and even getting transfusions of their own blood to discreetly boost their red blood cell counts. The biological passport would combat this increasingly sophisticated arsenal of tricks. Rather than ordinary spot-testing approaches, which look for unnatural ratios between biological constituents in a single sample or for direct chemical evidence of known doping agents, the passport allows investigators to see the big picture—any deviations from the rider’s test-established norm that might result from doping, even if the specific drug or tactic remains unknown [Scientific American].
(more…)
In an important step towards creating synthetic life forms, genetics pioneer George Church has produced a man-made version of the part of the cell that turns out proteins, which carry out the business of life. “If you going to make synthetic life that is anything like current life … you have got to have this … biological machine,” Church told reporters in a telephone briefing. And it can have important industrial uses, especially for manufacturing drugs and proteins not found in nature [Reuters].
Church’s team built a functional ribosome from scratch, molecule by molecule. Ribosomes are molecular machines that read strands of RNA and translate the genetic code into proteins. They are exquisitely complex, and previous attempts to reconstitute a ribosome from its constituent parts – dozens of proteins along with several molecules of RNA – yielded poorly functional ribosomes, and even then succeeded only when researchers resorted to “strange conditions” that did not recapitulate the environment of a living cell, Church said [Nature blog]. Next, the researchers want to produce man-made ribosomes that can replicate themselves.
(more…)
A compound often used in cosmetics and foods like ice cream may soon find a loftier use: Researchers say a topical gel containing the compound has shown great promise in preventing HIV infection. An effective vaginal gel would be particularly useful in Africa, where the virus is most commonly passed through heterosexual contact. Researchers say that while the current formulation of the compound does not provide 100 percent protection, it might greatly reduce a woman’s risk of being infected, and she could use it privately and without hurting her chances of pregnancy [Reuters].
The compound, glycerol monolaurate (GML), already has FDA approval because it’s used as an emulsifier in some foods and cosmetics; it’s also found naturally in breast milk. What’s more, the price for the compound is right: each dose used in the experiment cost about one cent.
The research marks a new approach to microbicides, as most other gels under development try to kill the virus outright or prevent it from attaching to cells. In contrast, GML stifles the host’s own inflammatory response that typically summons the immune cells targeted by the virus. “Even though it sounds counter-intuitive, halting the body’s natural defence system might actually prevent transmission and and rapid spread of the infection,” said chief investigator Ashley Haase [AFP]. Since GML prevents the immune cells from gathering, the HIV virus can’t infect them all and spread through the body.
(more…)
Researchers have tweaked HIV virus to create a strain that can infect monkeys, and say the development will allow better testing of vaccines and AIDS drugs. Until now, AIDS researchers used monkeys infected with simian immunodeficiency virus, or SIV. The virus is similar to ours, but it’s far from a perfect research tool…. Though SIV and HIV wreak similar havoc on their hosts’ immune systems, drugs affect them differently. While that makes SIV useful for studying how the disease progresses, it’s less useful for studying potential treatments [Wired News].
The new strain of HIV was developed by altering a single gene in the human version to allow it to infect a type of monkey called a pig-tailed macaque [Reuters]. The researchers replaced one HIV gene with the SIV version of the gene, which blocks virus-killing proteins made by the monkey and allows the infection to take hold. Even this altered virus doesn’t make the monkeys very sick, but while animal lovers may see that as a benefit, researchers see it as the final hurdle to overcome.
(more…)
The gas that creates the foul odor in rotten eggs, hydrogen sulfide, may hold the key to the next blockbuster drug to treat erectile dysfunction, according to a new study. Researchers studied penile tissue discarded by men having male-to-female sex-change operations and found that the tissue expresses hydrogen sulfide; researchers say the gas promotes erections by relaxing the tissue around blood vessels, allowing more blood to flow into the penis. Researchers say the findings raise the possibility of developing an alternative to Viagra by creating a drug that boosts production of the gas.
Viagra works by stimulating the production of nitric oxide, which usually relaxes the penile tissue. The physical result of the hydrogen sulfide treatment appears to be the same — relaxing the smooth-muscle in the penile tissue known as the corpus cavernosum, but it exploits a different chain of molecular tools. “This is a completely different pathway…. If it were to work out in humans, it would be a way to help out people that aren’t responding to Viagra and drugs like it” [Wired News], says urologist Jim Cummings, who was not involved in the new research.
(more…)
A simple urine test is being developed that would revolutionize the treatment of prostate cancer by differentiating between the benign and aggressive forms of the disease.
While prostate cancer is one of the most commonly diagnosed cancers in men, the real challenge for treatment tends to lie in measuring the progress of the disease. A person can live a long time with benign prostate cancer, but the aggressive kind of tumor grows much more quickly and requires urgent treatment. The current method for distinguishing between the two can involve several rounds of testing, including an invasive and painful biopsy.
The urine test, which will not be ready for at least another three to five years, would be an easy and inexpensive way to determine which type of cancer is present, researchers report in Nature [subscription required]. Research for the test began when doctors found that men with an aggressive form of prostate cancer carry elevated levels of a particular molecule in their urine [The Guardian].
(more…)
The first clinical trial of a therapy based on human embryonic stem cells has received the green light from the FDA, marking a scientific and political milestone for embryonic stem (ES) cell research. The biotech company, Geron Corporation, received approval today for a study that would inject neural stem cells into patients suffering from spinal cord injuries. The study will be mainly a test for safety, but functional improvements, which have been observed in animals trials, may be possible. “For us, it marks the dawn of a new era in medical therapeutics. This approach is one that reaches beyond pills and scalpels to achieve a new level of healing,” Geron Chief Executive Dr. Thomas Okarma said [Reuters].
ES cells are taken from embryos a few days after fertilization and have the potential to differentiate into any type of cell in the body. The undifferentiated cells can’t be used directly, because they can form cancers called teratomas. But they can be used in the lab to generate potentially inexhaustible supplies of all other types of cell[s] that might be needed for repair. The type to be used in the trial are neural stem cells called oligodendrocyte progenitor cells. These support other neurons in the brain and nerves by supplying growth factors and by producing the myelin sheaths that protect neurons from damage [New Scientist]. The FDA will allow Geron to implant these neural stem cells directly into the spinal cords of eight to ten paraplegics. The trials are expected to begin this summer, and may be carried out in multiple medical centers. The patients have not yet been recruited because the injections must take place within two weeks of the spinal cord injury, before scar tissue forms.
(more…)
A certain herd of 200 goats on a Massachusetts farm may look bucolic and quaint, but they actually comprise a living, breathing pharmaceutical factory, or “pharm.” The goats have been genetically engineered t0 produce a blood-thinning drug in their milk, and a report from the FDA has just declared that the drug is effective and safe for human use. An FDA advisory panel will make a recommendation this Friday on whether to approve the drug for sales; if the drug is approved, it would be the first application under new FDA regulations that allow animals to be genetically altered to produce drugs, model human disease, produce industrial or consumer products or improve their use as food [USA Today].
The goats, which are being bred by the biotech company GTC Biotherapeutics, produce a protein called antithrombin that prevents blood clotting. About 1 in 5,000 people don’t produce enough of the protein, putting them at risk of developing blood clots in their veins. Such clots can be extremely painful. If they break loose and travel through the bloodstream to the lungs or the brain, the consequences can be catastrophic. Pregnant women with the disorder are at high risk of miscarriage or stillbirth, because of blood clots in the placenta [AP]. While people with the deficiency typically manage their condition with conventional blood thinning drugs, such drugs aren’t suitable for surgeries and childbirth, when the risks of blood clots are particularly high–that’s where the new drug would come in. GTC is also developing further studies to test the drug in patients at risk for clots in non-hereditary conditions such as coronary bypass surgery [Reuters].
(more…)
Naturally lush lashes can be yours within 16 weeks, claims the drug company Allergan, which has received approval from the Food and Drug Administration (FDA) for Latisse, the first ever eyelash-enhancing medication. According to the company, clinical trials show that daily dabs of Latisse on the edges of eyelids produce longer, thicker lashes, although mild side effects are possible. Allergan plans to start selling prescription-only Latisse by the end of March.
The eyelash-enhancing ingredient in Latisse is bimatoprost, a compound derived from fatty acids that bind to receptors in the eyelashes that may be involved in the development and re-growth of hair follicles. Allergan has used bimatoprost since 2001 in Lumigan, an Rx eye drop that lowers eye pressure in people with glaucoma [Scientific American]. Drugmakers stumbled upon the idea for Latisse when doctors and patients noticed lusher lashes on glaucoma patients taking Lumigan. Soon after, some doctors began writing Lumigan prescriptions for cosmetic patients, and competitors raced to create eyelash products that used bimatoprost or similar ingredients [The Wall Street Journal, subscription required]. Allergan, which also produces Botox, has since sued 11 companies for patent infringement for using bimatopost to promote lash growth.
(more…)
An experimental drug has shown promise in preventing emphysema in mice exposed to cigarette smoke, giving researchers new hope that they’ll soon find a way to combat one of the most stubborn, untreatable, and common killers of humans. Even though the study focuses on emphysema in mice, the researchers suggest the drug could work in people by delaying or preventing chronic obstructive pulmonary disease, which encompasses emphysema and chronic bronchitis and is the fourth most common cause of death in the United States [Science News].
The drug, called CDDO-imidazole, or CDDO-Im, works by activating a gene called Nrf2, explains study coauthor Shyam Biswal. In prior research, Biswal and colleagues found that Nrf2 works as a “master gene,” turning on genes involved in protecting the lungs from pollution and cigarette smoke. “The Nrf2 pathway is the major antioxidant and detoxifying response in the lungs. Therapies targeting this pathway need to be developed and tested in patients,” said Biswal [Reuters].
(more…)
Pharmaceutical giant Wyeth is under scrutiny for its practice of paying ghostwriters to draft scientific journal articles favorable to its products and publishing them under the names of academic researchers. Some of the ghostwritten reports involve Wyeth’s hormone replacement therapy, Prempo, and deny the results of a federal study that linked the drug to an increased risk for breast cancer. The inquiries come as part of the Senate Finance Committee’s examination of “medical ghostwriting,” part of a broader probe into the influence of drug companies on the health-care industry [Wall Street Journal].
The investigation is being spearheaded by Senator Charles E. Grassley of Iowa, who last week sent a letter to Wyeth’s chairman requesting documentation of the company’s ghostwriting and publishing procedures. The letter [pdf] said Wyeth’s publications resembled “subtle advertisements rather than publications of independent research” and that “any attempt to manipulate the scientific literature, that can in turn mislead doctors to prescribe drugs that may not work and/or cause harm to their patients, is very troubling.” In response, a Wyeth spokesman accused Mr. Grassley of recycling old arguments and insisted that “The authors of the articles in question, none of whom were paid, exercised substantive editorial control over the content of the articles and had the final say, in all respects, over the content” [New York Times].
(more…)
If you could take a pill to boost your concentration and mental stamina, would you do it? Around the country, thousands of college students are already answering “yes” to that question and are using prescription medications like Ritalin as study aids, and researchers say the demand for such “smart pills” is likely to grow. Now, in a new essay, a group of neuroscientists and bioethicists is arguing that society shouldn’t frown on such practices; instead the authors assert that “we should welcome new methods of improving our brain function,” and that doing it with pills is no more morally objectionable than eating right or getting a good night’s sleep [Chronicle of Higher Education].
Stimulants like Ritalin and Adderall are prescribed for attention deficit hyperactivity disorder and are commonly used by people without a prescription to help them focus their attention, while a narcolepsy drug called Provigil is sometimes used by people trying to keep their brains alert and awake. The new essay cited a recent survey that found nearly 7 percent of students in U.S. universities have used prescription stimulants, and on some campuses, as many as a quarter of students have used the drugs for non-therapeutic purposes. “It’s a felony, but it’s being done,” [coauthor Martha] Farah said [Reuters].
(more…)
A promising target for next-generation cancer therapies might not be a target after all, according to a new study in Nature [subscription required]. The work calls into question the “cancer stem cell theory,” which claims that a rare class of cells, cancer stem cells, are responsible for initiating and spreading cancer tumors. But by tweaking previous experimental procedures, researchers working with human melanoma cells in mice now report that cancer stem cells are much more prevalent that previously thought. “We’re not trying to claim there is no merit to the field, but we think that the frequency of cancer stem cells will be much higher,” said [co-author] Sean Morrison… . “And there will be some cancers like melanoma where lots of cells will be tumorigenic and it won’t be possible to treat those cancers by treating a small subset of cells” [Wired Science].
Cancer stem cells—so-called because they share genetic similarities with standard stem cells—were first identified in 1994 and since then have been reported in cancers of the brain, breast, colon, and pancreas. They provided a well-defined target for cancer drugs since they were thought to number only a few in a million. Like evil relatives of standard organ-forming stem cells, cancer stem cells build tumors. It’s an appealing idea because it provides a new, well defined target for treatment [Wired News]. However, not everyone in the field was smitten with the new theory.
(more…)
The official death toll from the cholera outbreak in Zimbabwe has climbed to nearly 500, according to the World Health Organization. But doctors on the ground say the actual fatalities may be closer to 1,000, with more than 12,000 infected since the start of the outbreak in August. Severe shortages of clean water, food, and medicine have allowed the normally treatable illness to ravage the country. Poorer areas have been without running water for months and just this week, the government cut off water to the nation’s capital, Harare. “The country is reaching a catastrophic level, in terms of food, health delivery, education,” said Morgan Tsvangirai, the MDC [opposition party] leader. “Everything seems to be collapsing around us” [Times Online].
Authorities say they have run out of water-purifying chemicals and have therefore shut down the water system in an attempt to contain the waterborne disease. But without running water, sanitation systems are nonexistent and sewage lies in the open air. “Proper hygiene is the best protection against cholera and you can’t do that without clean water,” [BBC News] said Marcus Bachmann of Doctors Without Borders. Residents have resorted to digging shallow wells and using contaminated water despite the government’s warning to use only boiled water. “We are afraid but there is no solution, most of the time the electricity is not available so we just use the water,” resident Naison Chakwicha said [USA Today]. The Health Minister has even asked residents to stop shaking hands. “Although it’s part of our tradition to shake hands, it’s high time people stopped,” he said [CNN].
(more…)
To mark World AIDS Day yesterday, researchers engaged in a “thought experiment” meant both to demonstrate the challenges and the possibilities confronting a world beset by the HIV virus. What would happen, they asked, if everyone was tested annually for HIV, and all people with positive results were immediately put on antiretroviral drugs? In a new study published in the journal The Lancet [subscription required], researchers predicted what the effects of such a policy would be in South Africa. They worked out that treating everyone with the virus with antiretroviral drugs would reduce incidence from 20 per 1000 people to just 1 per 1000 within 10 years…. That’s because the drugs keep levels of the virus in the blood down, making people less infectious – even if they have unsafe sex [New Scientist].
Currently, people have to seek out HIV tests, and those who don’t engage in high-risk behavior (like unsafe sex or intravenous drug use) often never get tested. In addition, the expensive antiretroviral drugs currently aren’t prescribed to HIV-positive patients until their immune systems are compromised and they begin to show symptoms of AIDS. The researchers argue in their article that present policies aren’t working, as 33 million people around the world are currently infected with HIV. The American College of Physicians also released new recommendations this week, advising doctors to routinely screen all patients if possible.
(more…)
